Roivant Sciences (ROIV) Change in Accured Expenses (2020 - 2025)
Roivant Sciences (ROIV) posted Change in Accured Expenses of -$3.9 million for Q4 2025, down 131.15% on a QoQ basis from $12.5 million in Q3 2025, and up 80.01% year-over-year from -$2.2 million in Q4 2024.
Roivant Sciences (ROIV) Change in Accured Expenses (2020 - 2025) Analysis & Trends
Roivant Sciences' Change in Accured Expenses history runs 6 years deep, the most recent figure standing at -$3.9 million for Q4 2025.
- Quarterly Change in Accured Expenses rose 80.01% year-over-year to -$3.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$35.9 million (up 30.67% YoY) and the FY2025 annual result came in at -$10.1 million, down 321.87% from the prior year.
- Change in Accured Expenses was -$3.9 million for Q4 2025 at Roivant Sciences, down from $12.5 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $37.6 million in Q3 2023 and bottomed at -$50.0 million in Q2 2023.
- A 5-year average of -$1.3 million and a median of -$3.9 million in 2025 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2021 — Change in Accured Expenses soared 281.76% — and 2023, when it slumped 376.83%.
- Roivant Sciences' Change in Accured Expenses stood at $35.6 million in 2021, then plunged by 83.97% to $5.7 million in 2022, then plunged by 376.83% to -$15.8 million in 2023, then dropped by 23.58% to -$19.5 million in 2024, then jumped by 80.01% to -$3.9 million in 2025.
- Business Quant data shows ROIV's Change in Accured Expenses at -$3.9 million in Q4 2025, $12.5 million in Q3 2025, and -$25.0 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -16.82 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -16.74 Mn |
| 10 | Roivant Sciences | 24.35 Bn | 25.12 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.90 Mn |
| Dec 31, 2025 | -3.90 Mn |
| Sep 30, 2025 | 12.52 Mn |
| Sep 30, 2025 | 12.52 Mn |
| Jun 30, 2025 | -25.00 Mn |
| Jun 30, 2025 | -25.00 Mn |
| Dec 31, 2024 | -19.51 Mn |
| Dec 31, 2024 | -19.51 Mn |
| Sep 30, 2024 | 21.11 Mn |
| Sep 30, 2024 | 21.11 Mn |
| Jun 30, 2024 | -37.58 Mn |
| Jun 30, 2024 | -37.58 Mn |
| Dec 31, 2023 | -15.79 Mn |
| Dec 31, 2023 | -15.79 Mn |
| Sep 30, 2023 | 37.57 Mn |
| Sep 30, 2023 | 37.57 Mn |
| Jun 30, 2023 | -49.96 Mn |
| Jun 30, 2023 | -49.96 Mn |
| Dec 31, 2022 | 5.70 Mn |
| Dec 31, 2022 | 5.70 Mn |